What Yarrow Bioscience, Inc. reported on November 12, 2026
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toDec 31, 2024 | Change |
|---|
| Total Revenue | $97K | $84K | +15.48% |
| Profit | -$3M | -$12M | +74.99% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Earnings calls
NewThe latest call
FetchingYarrow Bioscience, Inc. reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
What management said
“We made significant progress in the third quarter, including dosing our first patient in the Phase 2a portion of the DIRECTION-GD trial and strengthening our balance sheet through the completion of our merger and subsequent public offering,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
How the share price reacted
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Close before
$18.10
Nov 11, 2026
Close after
$17.99
Nov 13, 2026
Move
-0.61%
0 shares traded, against a normal 146.84K
What Yarrow Bioscience, Inc. does
Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, a potential first-in-class anti-TSHR monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both GD and TED.
The company’s own description, as it appears at the foot of the release.
The quote, the company description and the latest quarter come from Yarrow Bioscience’s earnings press release (an Item 2.02 8-K) filed November 12, 2026. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. Read the release on EDGAR Share prices are split- and dividend-adjusted.
